Physician profile
Kristie Thomas
NPI 1245632975
$7,276.74
in general payments reported to CMS, 2019-2025
25 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,632 · 2022: $1,129 · 2023: $789 · 2024: $1,473 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,437 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,436.58 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,422.05 | 2021-2025 | |
| Janssen Biotech, INC. | $1,107.84 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $807.73 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $463.70 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Phathom Pharmaceuticals, INC. | $343.52 | 2024-2025 | Voquezna |
| Pfizer INC. | $288.74 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $285.63 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $249.48 | 2021-2023 | |
| Gilead Sciences, INC. | $210.77 | 2021-2025 | |
| Celltrion USA INC. | $154.18 | 2024-2025 | Vegzelma |
| Lilly USA, LLC | $129.28 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $126.23 | 2021-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $115.80 | 2021-2022 | |
| Madrigal Pharmaceuticals | $99.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $83.44 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $74.99 | 2021-2022 | |
| Redhill Biopharma INC. | $70.07 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $57.79 | 2021-2023 | Rebyota |
| Amgen INC. | $51.72 | 2021 | |
| Ardelyx, INC. | $49.23 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $19.43 | 2021 | |
| Cardiovascular Systems INC. | $18.46 | 2022 | |
| Evoke Pharma, INC. | $16.30 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.70 | 2021 | |
| Novo Nordisk INC | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.